Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Sign or Symptom > Resting Tremor

Resting Tremor

Resting Tremor is an involuntary, rhythmic shaking of a body part that occurs when the muscle is at rest.
It is a common symptom of neurological disorders, such as Parkinson's disease, and can significantly impact a person's quality of life.
The underlying causes of resting tremor are not fully understood, but it is often associated with dysfunction in the basal ganglia, a region of the brain responsible for motor control.
Accurate assessment and monitoring of resting tremor are crucial for effective disease management and treatment.
The PubCompare.ai platform can help researchers optimize their resting tremor investigations by providing easy access to the most relevant protocols and enabling accurate comparisons to identify the best approaches, enhancing research reproducibility and accuracy.

Most cited protocols related to «Resting Tremor»

1
Early Parkinson's Disease Cohort Study
Cited 48 times
PD and HC subjects of similar age and gender from 24 study sites in the US (18), Europe (5) and Australia (1) were enrolled after obtaining informed consent. We acknowledge that the early PD cohort likely includes a small number of subjects with other DAT deficit parkinsonian syndromes such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and cortical basal syndrome (CBS), which may be indistinguishable from PD at the earliest stages of disease. At each study visit, the investigators reassess the subject diagnosis to identify any non‐PD subjects.
This study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice (GCP) guidelines after approval of the local ethics committees of the participating sites. At enrollment, PD subjects were required to be age 30 years or older, untreated with PD medications (levodopa, dopamine agonists, MAO‐B inhibitors, or amantadine), within 2 years of diagnosis, Hoehn and Yahr <3, and to have either at least two of resting tremor, bradykinesia, or rigidity (must have either resting tremor or bradykinesia) or a single asymmetric resting tremor or asymmetric bradykinesia. All PD subjects underwent dopamine transporter (DAT) imaging with 123I Ioflupane or vesicular monoamine transporter (VMAT‐2) imaging with 18F AV133 (Australia only) and were only eligible if DAT or VMAT‐2 imaging demonstrated dopaminergic deficit consistent with PD in addition to clinical features of the disease. Study investigators evaluated enrolled PD subjects to assess absence of current or imminent (6 months) disability requiring PD medications, though subjects could initiate PD medications at any time after enrollment if the subject or investigator deemed it clinically necessary. Those subjects screened as potential PD subjects who were ineligible due to DAT or VMAT‐2 scans without evidence of dopaminergic deficit (SWEDD) were eligible to be enrolled in a SWEDD cohort.4 HC subjects were required to be age 30 years or older without an active, clinically significant neurological disorder or a first‐degree relative with PD. All enrolled subjects agreed to complete all study evaluations, including lumbar puncture.
PD and SWEDD subjects were excluded if they had a clinical diagnosis of dementia or had taken PD medications within 60 days of baseline or for longer than 60 days in total. HC subjects were excluded if they had a Montreal Cognitive Assessment (MoCA) total score ≤26. All subjects were excluded if they were treated with neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative within 6 months or were currently treated with anticoagulants that might preclude safe completion of the lumbar puncture.
Marek K., Chowdhury S., Siderowf A., Lasch S., Coffey C.S., Caspell‐Garcia C., Simuni T., Jennings D., Tanner C.M., Trojanowski J.Q., Shaw L.M., Seibyl J., Schuff N., Singleton A., Kieburtz K., Toga A.W., Mollenhauer B., Galasko D., Chahine L.M., Weintraub D., Foroud T., Tosun‐Turgut D., Poston K., Arnedo V., Frasier M, & Sherer T. (2018). The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 5(12), 1460-1477.
Publication 2018
123I-ioflupane Amantadine Amphetamine Anticoagulants Antipsychotic Agents Bradykinesia Cortex, Cerebral Dementia Diagnosis Disabled Persons Dopamine Agonists Gender Hydrochloride, Dopamine Levodopa Methyldopa Methylphenidate Metoclopramide Monoamine Oxidase Inhibitors Multiple System Atrophy Muscle Rigidity Nervous System Disorder Parkinsonian Disorders Pharmaceutical Preparations Progressive Supranuclear Palsy Punctures, Lumbar Radionuclide Imaging Regional Ethics Committees Reserpine Resting Tremor SLC6A3 protein, human Syndrome Vesicular Monoamine Transport Proteins Volumetric-Modulated Arc Therapy
2
Parkinson's Disease Biomarker Program
Cited 14 times
Established November 2012, the PDBP seeks to identify biomarkers to improve therapeutic development in PD. The PDBP serves both as a biomarker discovery engine and a resource for clinical information and biospecimens. The PDBP includes 1) biomarker hypothesis testing and collection of clinical data and biospecimens, 2) identification of novel PD biomarkers, 3) biospecimen banking and distribution, and 4) data management through the DMR.
NINDS established the PDBP based on the vision that biomarker discovery and replication was needed to improve the efficiency and outcome of therapeutic clinical trials. Funding opportunity announcements (see RFA-NS-12-010, and RFA-NS-12-011) solicited applications, which underwent peer review. NINDS Advisory Council input then led to selection of projects based on scientific merit (as judged in review) and uniqueness of the project (either scientifically or in terms of the cohort recruited, or both) and considered in the space of existing efforts. The NINDS invested approximately $5M per year in the PDBP; three projects (under the U18 mechanism) are three years; the others are five years, allowing longitudinal follow-up for clinical cohorts. Milestones (go-no-go decision points) are used by NINDS to maximize scientific progress and compliance with rapid sharing.
There are several key differences between PDBP and other programs. PPMI’s goal is validation of biomarker discovery projects and participants must not be on anti-PD medications at the time of enrollment. BioFIND is a cross-sectional study for the characterization and collection of samples for biomarkers discovery from participants with resting-tremor predominant PD and controls. BioFIND does not have hypothesis testing included as a core component of its activities. However, hypothesis-based discovery projects, funded separately, are expected to utilize the collected samples and associated data. PDBP fills the gap in between these two and complements both by including longitudinal collection and by creating a resource for replication of early discoveries made in BioFIND. PDBP is agnostic regarding the use of DaTScan’s for enrollment, resting tremor predominance, and treatment status, and thus represents the typical participant for a future clinical trial. Additionally, each funded PDBP project pursues a biomarkers discovery project.
Rosenthal L.S., Drake D., Alcalay R.N., Babcock D., Bowman F.D., Chen-Plotkin A., Dawson T.M., Dewey RB J.r., German D., Huang X., Landin B., McAuliffe M., Petyuk V.A., Scherzer C.R., St Hillaire-Clarke C., Sieber B.A., Sutherland M., Tarn C., West A., Vaillancourt D., Zhang J, & Gwinn K. (2015). The NINDS Parkinson’s Disease Biomarkers Program. Movement disorders : official journal of the Movement Disorder Society, 31(6), 915-923.
Publication 2015
Biological Markers Complement System Proteins DNA Replication Peer Review Pharmaceutical Preparations Resting Tremor Specimen Collection
3
MIHG GWAS Parkinson's Disease Protocol
Cited 13 times
Samples in the MIHG GWAS include individuals with PD collected by one of 13 ascertainment centers in the PD Genetics Collaboration (Scott et al. 2001 (link)) or by the Morris K. Udall Parkinson Disease Center of Excellence (J.M. Vance, PI) ascertainment core. These participants were recruited by participating movement disorder and neurology clinics, referrals, and advertisements. Unaffected spouse and friend controls were recruited when available and willing to participate. All participants provided written informed consent, in accord with protocols established by institutional review boards at each center.
All individuals with PD were examined by a board-certified neurologist. A neurological exam and standard clinical evaluation was performed on all participants with PD. Affected individuals exhibited at least two cardinal symptoms of PD, e.g. bradykinesia, resting tremor, and rigidity and no other causes of Parkinsonism or atypical clinical features. Unaffected individuals had no symptoms of PD upon physical examination and self-reported symptom questionnaire (Rocca et al. 1998 (link)). Individuals were excluded if there was a history of encephalitis, neuroleptic therapy within one year before diagnosis, evidence of normal pressure hydrocephalus, or a clinical course with unusual features suggesting atypical or secondary Parkinsonism. Additionally, a blood sample, family history, medical history, and standard cognitive test (Blessed Orientation Memory Concentration (BOMC) (Katzman et al. 1983 (link)) test or Modified Mini Mental Status exam (3MS) (Folstein et al. 1975 (link))) were obtained for each individual. To ensure diagnostic consistency across sites, clinical data for all participants were reviewed by a panel consisting of a board-certified neurologist with fellowship training in movement disorders, a board certified neurologist and medical geneticist, and a certified physician assistant.
Edwards T.L., Scott W.K., Almonte C., Burt A., Powell E.H., Beecham G.W., Wang L., Züchner S., Konidari I., Wang G., Singer C., Nahab F., Scott B., Stajich J.M., Pericak-Vance M., Haines J., Vance J.M, & Martin E.R. (2010). Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Annals of human genetics, 74(2), 97-109.
Publication 2010
Antipsychotic Agents BLOOD Bradykinesia Cognitive Testing Diagnosis Encephalitis Ethics Committees, Research Fellowships Friend Genome-Wide Association Study Hydrocephalus, Normal Pressure Memory Mini Mental State Examination Movement Disorders Muscle Rigidity Neurologists Parkinson Disease Parkinsonian Disorders Physical Examination Physician Assistant Resting Tremor Secondary Parkinson Disease Spouse Therapeutics
4
PEG Study: Parkinson's Epidemiology in California
Cited 10 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Aftercare Apraxias Blood Vessel Bradykinesia Brain Neoplasms Cerebellum Cerebrovascular Disorders Cogwheel Rigidity Dopamine Dopaminergic Agents Eligibility Determination Ethics Committees, Research Genes Hypotension, Orthostatic Infection Levodopa Movement Disorders Muscular Atrophy Nervous System Disorder Neurologists One-Person Household Ophthalmoplegia Parkinsonian Disorders Partial Paralysis (Paresis) Vocal Cords Patients Progressive Supranuclear Palsy Reflex Resting Tremor Terminally Ill Veterans Wounds and Injuries
5
Diagnostic Criteria for Parkinsonism Subtypes
Cited 9 times
Our diagnostic criteria included two steps: the definition of parkinsonism as a syndrome and the definition of types of parkinsonism within the syndrome. Parkinsonism was defined as the presence of at least two of four cardinal signs: rest tremor, bradykinesia, rigidity, and impaired postural reflexes. Among the persons who fulfilled the criteria for parkinsonism, we applied the diagnostic criteria listed in Table 1 to classify the type of parkinsonism. In addition, we used clinical characteristics to group patients with parkinsonism into presumed synucleinopathies or presumed tauopathies.7 (link)–9 (link) Synucleinopathies included PD, parkinsonism with dementia, and MSA.7 (link)–8 (link) Tauopathies included PSP and CBS.9 (link)Patients with uncertain underlying proteinopathy were included in the category “other types of parkinsonism.” This category included patients who did not have enough clinical information to fulfill the criteria for a particular type of parkinsonism (parkinsonism unspecified) and patients with types of parkinsonism not associated with a specific pathological hallmark (e.g., drug-induced parkinsonism, vascular parkinsonism, and secondary parkinsonism).
Savica R., Grossardt B.R., Bower J.H., Ahlskog J.E, & Rocca W.A. (2013). Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA neurology, 70(7), 859-866.
Publication 2013
Blood Vessel Bradykinesia Dementia Diagnosis Muscle Rigidity Parkinsonian Disorders Patients Pharmaceutical Preparations Proteostasis Deficiencies Reflex Resting Tremor Secondary Parkinson Disease Syndrome Synucleinopathies Tauopathies

Most recents protocols related to «Resting Tremor»

1
Parkinson's Disease Tremor Measurement Protocol
The research has been approved by the Chinese Clinical Trial Registry (Registration No.: ChiCTR2100054804) and the local Ethics Committee of Shanghai Jiao Tong University, China (Approved No. of Ethic Committee: 2019 Clinical Trial No. 136). All subjects provided written consent after being informed of the purpose and the procedures of the experiment. The overall experiment was strictly performed in accordance with all relevant guidelines and regulations of the institutional review board and the Declaration of Helsinki. Patients were recruited by the department of neurology of Rui Jin Hospital (Shanghai, China). All of them were out-patients with upper limb tremor resulted from Parkinson's disease (Excluded N = 11; Not meeting the inclusion criteria N = 7; Declined to participate N = 4) (Figure 1).
The inclusion criteria for subjects were: (1) age between 50 and 80 years old, (2) confirmed diagnosis of idiopathic Parkinson's disease according to the MDS clinical diagnostic criteria for PD (Postuma et al., 2015 (link)), (3) symptom of upper limb tremor (rest tremor or postural tremor) resulted from PD, and (4) modified Hoen & Yahr (H&Y) Stage 1 to 3 (Hoehn and Yahr, 1967 (link)). The exclusion criteria included: (1) history of other diseases that may lead to pathological tremor, such as essential tremor (Deuschl et al., 1998 (link)), (2) under the treatment of other neuromodulation therapy, such as DBS, within recent 1 month, (3) history of mental problems, including anxiety, dementia, hallucination or delusion etc., (4) strong reliance on anti-Parkinson medications, or (5) history of cognitive disorder [Mini-mental State Examination (MMSE) score ≤ 16] (Tombaugh and McIntyre, 1992 (link)).
The average disease duration of PD among all subjects [7M/6F, all right-handed, aged 67.5 ± 4.9 (mean ± SD)] were 4.38 ± 1.86 (mean ± SD) years. The Unified Parkinson's Disease Rating Scale (UPDRS) score ranged from 20 to 78 [31.7 ± 15.4 (mean ± SD)] while the modified H&Y stage ranged from 1.0 to 3.0 [1.8 ± 0.8 (mean ± SD)]. The tremor was found to be lateralized in all subjects. Throughout the manuscript, we refer to the more-affected side (MAS) as the side of body exhibiting more severe tremor, which was determined visually by an experienced physician, while the less-affected side (LAS)was defined as the other. Of all subjects, about half (n = 7) were found to be more-affected by tremor on the left side with the other half (n = 6) on the right side. The average levodopa-equivalent daily dose (LEDD) among all subjects was 278.8 ± 203.3 (mean ± SD) mg according to the calculation protocol provided by Tomlinson et al. (2010 (link)). In order to exclude drug effects, all subjects were told to discontinue anti-Parkinson medications on the day of the experiment, which ensured a withdrawal period of more than 12 h. Anti-Parkinson medications were resumed immediately after the experiment session of the day.
Zhang B., Huang F., Liu J, & Zhang D. (2023). Bilateral transcranial direct current stimulation may be a feasible treatment of Parkinsonian tremor. Frontiers in Neuroscience, 17, 1101751.
Publication 2023
Anxiety Chinese Cognition Disorders Delusions Dementia Diagnosis Essential Tremor Ethics Committees Ethics Committees, Research Hallucinations Human Body Levodopa Mini Mental State Examination Outpatients Parkinson Disease Patients Pharmaceutical Preparations Physicians Regional Ethics Committees Reliance resin cement Respiratory Diaphragm Resting Tremor Static Tremor Therapeutics Tremor Tremor, Limb Upper Extremity
2
Quantifying Upper Limb Tremor: Acceleration and EMG Signals
In order to quantify upper limb tremor for comparison, we collected two continuous tremor signals, which were tremor acceleration and EMG signals, respectively. Before experiment, the tremor type (postural tremor/resting tremor) to record of each subject was decided independently by a physician after patient's enrollment. The main principle of choosing the main tremor type is tremor intensity and stability. Intentional tremor was not considered in our research since it is difficult to standardize motion. For subjects whose main tremor type is resting tremor, we had them seated comfortably with arms fully supported on armrests and recorded their tremor. For the others, postural tremor was inspected with seated subject stretching the whole upper limb forward and maintaining the posture for some time (Zhang et al., 2018 (link)). Additional requirements in recording postural tremor included: (1) fingers closed, (2) palms facing downward, and (3) seated upright.
All data was recorded through a commercial device system named the Biometrics Datalog (Biometrics Inc., the USA), along with a three-axis accelerometer sensor and four surface EMG (sEMG) sensors. The accelerometer sensor was fixed onto the third knuckle of the middle finger on the more affected side. Four sEMG sensors were attached respectively onto the muscle bellies of the flexor carpi radialis (FCR), the flexor carpi ulnaris (FCU), the extensor carpi radialis (ECR) and the extensor carpi ulnaris (ECU). The data of tremor acceleration and EMG signals were both digitized into 1,000 Hz and simultaneously recorded. From each subject, we obtained a 5-min sequential data package comprising tremor acceleration and EMG signals.
Zhang B., Huang F., Liu J, & Zhang D. (2023). Bilateral transcranial direct current stimulation may be a feasible treatment of Parkinsonian tremor. Frontiers in Neuroscience, 17, 1101751.
Publication 2023
Acceleration Action Tremor Arecaceae Arm, Upper Continuous Tremor Epistropheus Fingers Medical Devices Metacarpophalangeal Joint Muscle Tissue Physicians Resting Tremor Static Tremor Surface Electromyography Tremor Tremor, Limb Upper Extremity Wrist
3
Precipitated and Spontaneous Opioid Withdrawal
Precipitated withdrawal was examined immediately after a 1 mg/kg subcutaneous (s.c.) dose of naloxone, or equivalent volume of saline for controls, and spontaneous withdrawal was conducted 24 h after morphine was removed. Mice were acclimated in the behavior room 1 h prior to observations and were placed in a clear cylinder for 30 m before testing began. Somatic withdrawal signs were scored live and the total number of episodes of ptosis, diarrhea, teeth chattering, resting tremor, gnawing, genital licking, head and body shakes, backing, scratching, and jumping were tallied as described previously [32 (link), 36 (link)].
Eacret D., Manduchi E., Noreck J., Tyner E., Fenik P., Dunn A.D., Schug J., Veasey S.C, & Blendy J.A. (2023). Mu-opioid receptor-expressing neurons in the paraventricular thalamus modulate chronic morphine-induced wake alterations. Translational Psychiatry, 13, 78.
Publication 2023
Diarrhea Diploid Cell Genitalia Head Human Body Mice, House Morphine Naloxone Prolapse Resting Tremor Saline Solution Tooth Tremor
4
Comprehensive Motor and Cognitive Assessment in Parkinson's
The presence and severity of motor symptoms along with the cognitive status were assessed in both groups using the motor section of MDS-UPDRS-III and the Montreal Cognitive Assessment (MoCA), respectively [61 (link), 62 (link)]. To quantify the severity of specific manifestations of PD, several subscores were calculated based on subsets of MDS-UPDRS-III items: MDS-UPDRS-III tested hand/other hand, MDS-UPDRS-III tested foot/other foot, MDS-UPDRS-III bradykinesia tested hand/other hand, and MDS-UPDRS-III bradykinesia tested foot/other foot. The PD group also underwent an additional instrumented assessment of motor symptoms using the Kinesia ONE wearable sensor (Great Lakes NeuroTechnologies Inc, Cleveland, OH). The Kinesia ONE device is approved by the Food and Drug Administration (FDA), provides clinically validated objective outcomes to track the severity of motor symptoms, and is used around the globe in clinical trials for PD, essential tremor, and other movement disorders [63 (link)–65 (link)]. The sensor includes a triaxial accelerometer and gyroscope and is designed to be worn on the index finger or shoe heel depending on the symptom being assessed. In this study, both sides were tested using pre-defined tasks based on the MDS-UPDRS-III scale. Data from the motion sensor was used to calculate severity scores on a 0–4 rating scale for specific upper limb tasks available in the MDS-UPDRS-III such as finger tapping, hand movements, pronation-supination movements of hands, postural tremor of the hands, kinetic tremor of the hands, rest tremor of the hands (i.e., MDS-UPDRS-III 3.4, 3.5, 3.6, 3.15, 3.16, and 3.17 respectively), lower limb tasks such as toe tapping, leg agility, gait (i.e., MDS-UPDRS-III 3.7, 3.8, 3.10 and 3.11 respectively), and general symptoms such as dyskinesia. Unlike the MDS-UPDRS-III, Kinesia ONE also provides severity scores for key movement characteristics such as speed, amplitude, and rhythm for all upper limb tasks measuring bradykinesia. The bradykinesia-related scores for the tested side are listed in Table 1. Importantly, all motor tests in PD were conducted off antiparkinsonian medication [66 (link)], with testing following an overnight withdrawal from PD medication of at least 12 hours.
Chung J.W., Knight C.A., Bower A.E., Martello J.P., Jeka J.J, & Burciu R.G. (2023). Rate control deficits during pinch grip and ankle dorsiflexion in early-stage Parkinson’s disease. PLOS ONE, 18(3), e0282203.
Publication 2023
Action Tremor AN 12 Antiparkinson Agents Bradykinesia Cognition Dyskinesias Essential Tremor Eye Fingers Foot Heel Kinetics Lower Extremity Medical Devices Movement Movement Disorders Pharmaceutical Preparations Pronation Resting Tremor Static Tremor Supination Symptom Assessment Upper Extremity
5
Comprehensive Tremor Assessment Protocol
We used relevant sections from the Fahn–Talosa–Marin Tremor Rating Scale (FTM-TRS)—which contains parts A, B, and C—to assess limb tremors and cranial tremors (17 ). For limb tremor scoring, we summed the postural/kinetic tremor scores of items 5 and 6 in part A and all items in part B for upper-limb-action tremor scores, whereas we summed the postural/kinetic tremor scores of items 8 and 9 in part A for lower-limb-action tremor scores. Limb rest tremor scores were calculated from the rest of the tremor part of items 5 and 6 and items 8 and 9 in part A.
We evaluated the neck, voice, and facial tremors using items 1, 3, and 4 in part A (17 ), respectively, and their sum represented the cranial tremor score. When scored for at least one point of a body part or a tremor type, the patients were considered to have the presence of a tremor in that corresponding body part or tremor type.
Intention tremor, evaluated by the finger-nose-finger test, was defined as tremor amplitude that increased during movements close to the target (4 (link)). The presence of intention tremor was defined as having either probable intention tremor in both arms or definite/incapacitating intention tremor in at least one arm (4 (link)).
Huang H., He X., Shen Q., Zhang D., Bao Y., Xu F., Luo A., Liu L., Yang X, & Xu Y. (2023). Prevalence and risk factors for abnormal tandem gait in patients with essential tremor syndrome: A cross-sectional study in Southwest China. Frontiers in Neurology, 14, 998205.
Publication 2023
Action Tremor Cranium Face Fatty Acid Hydroxylase-Associated Neurodegeneration Fingers Kinetics Movement Neck Nose Parts, Body Patients Resting Tremor Static Tremor Tremor Tremor, Limb

Top products related to «Resting Tremor»

1
Matlab by MathWorks
Sourced in United States, United Kingdom, Germany, Canada, Japan, Sweden, Austria, Morocco, Switzerland, Australia, Belgium, Italy, Netherlands, China, France, Denmark, Norway, Hungary, Malaysia, Israel, Finland, Spain
MATLAB is a high-performance programming language and numerical computing environment used for scientific and engineering calculations, data analysis, and visualization. It provides a comprehensive set of tools for solving complex mathematical and computational problems.
2
Spss version 26 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Austria, Canada, Belgium, Spain
SPSS version 26 is a statistical software package developed by IBM. It is designed to perform advanced statistical analysis, data management, and data visualization tasks. The software provides a wide range of analytical tools and techniques to help users understand and draw insights from their data.
3
Datscan by GE Healthcare
Sourced in United Kingdom
DaTSCAN is a diagnostic imaging agent used in conjunction with single-photon emission computed tomography (SPECT) to detect the presence of dopamine transporters in the brain. It is primarily used to assist in the evaluation of patients with suspected Parkinsonian syndromes, such as Parkinson's disease.
4
Figure of eight coil by Magstim
Sourced in United Kingdom
The Figure-of-eight coil is a type of magnetic coil used in transcranial magnetic stimulation (TMS) equipment. It consists of two circular coils arranged in a figure-of-eight configuration. The coil generates a localized and focused magnetic field that can be used to stimulate specific areas of the brain.
5
Super rapid2 by Magstim
Sourced in United Kingdom
The Super Rapid2 is a lab equipment product from Magstim. It is a magnetic stimulator device that generates magnetic pulses to stimulate neural activity.
6
Spss v21 by IBM
Sourced in United States, United Kingdom, Germany, Japan, Spain, Denmark, Austria
SPSS v21 is a statistical software package developed by IBM. It is designed to analyze and manipulate data, providing a range of statistical tools and techniques for researchers and analysts. The software offers a user-friendly interface and a comprehensive set of data management and analysis capabilities.
7
Spss version 24 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, China, Spain, Ireland
SPSS version 24 is a statistical software package developed by IBM. It provides a comprehensive set of tools for data analysis, including techniques for descriptive statistics, regression analysis, and predictive modeling. The software is designed to help users interpret data, identify trends, and make informed decisions based on statistical insights.
8
Spss v23 by IBM
Sourced in United States, United Kingdom, Japan, Belgium, Italy, Austria, Germany, Australia, France
SPSS v23 is a statistical software package developed by IBM. It is designed to analyze and manipulate data. The software provides a range of tools and functions for data management, statistical analysis, and reporting.
9
Spss version 21 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Austria, Belgium, Denmark, China, Israel, Australia
SPSS version 21 is a statistical software package developed by IBM. It is designed for data analysis and statistical modeling. The software provides tools for data management, data analysis, and the generation of reports and visualizations.
10
Magnetom avanto scanner by Siemens
Sourced in Germany
The Magnetom Avanto scanner is a magnetic resonance imaging (MRI) system designed and manufactured by Siemens. It is a powerful diagnostic tool used to generate detailed images of the human body's internal structures. The Magnetom Avanto employs advanced magnetic and radio frequency technologies to capture high-resolution images that assist healthcare professionals in the diagnosis and monitoring of various medical conditions.

More about "Resting Tremor"

Resting tremor, also known as parkinsonian tremor, is an involuntary, rhythmic shaking of a body part that occurs when the muscle is at rest.
This neurological symptom is commonly associated with Parkinson's disease, a progressive movement disorder, and can significantly impact an individual's quality of life.
The underlying causes of resting tremor are not fully understood, but it is often linked to dysfunction in the basal ganglia, a region of the brain responsible for motor control.
Accurate assessment and monitoring of resting tremor are crucial for effective disease management and treatment.
The PubCompare.ai platform can help researchers optimize their resting tremor investigations by providing easy access to the most relevant protocols and enabling accurate comparisons to identify the best approaches, enhancing research reproducibility and accuracy.
Researchers can utilize various tools and techniques to study resting tremor, such as MATLAB for data analysis, SPSS (versions 21, 23, 24, and 26) for statistical analysis, and DaTSCAN for imaging of dopamine transporters.
Additionally, the Figure-of-eight coil and Super Rapid2 can be employed for transcranial magnetic stimulation (TMS) studies related to resting tremor.
These advanced tools and techniques can help uncover the mechanisms underlying this debilitating symptom and drive the development of more effective treatments.
OtherTerms: parkinsonian tremor, involuntary shaking, basal ganglia, MATLAB, SPSS, DaTSCAN, Figure-of-eight coil, Super Rapid2